EC Number   |
Inhibitors |
Structure |
|---|
    2.2.1.1 | RNAi |
transketolase-like-1 gene is significantly downregulated in human colon cancer cell line cells transfected with small interfering RNA transketolase-like-1 constructs compared with cells transfected with control vector and cells without transfection. Anti-transketolase-like-1 small interfering RNA construct significantly decreases the level of transketolase in the transfected human colon cancer cell line cells, arrests them in G0/G1 phase and substantially inhibits cell proliferation |
 |
| 2.2.1.1 | RNAi |
inhibits expression of TKTL1, whereas total transketolase activity is dramatically downregulated and proliferation of cancer cells is significantly inhibited in CNE cells |
|
| 2.2.1.1 | sulfate |
- |
  |
| 2.2.1.1 | thiamine thiazolone |
retains thiamine pyrophosphokinase activity, is a significantly better binder to transketolase than thiamine |
|
| 2.2.1.1 | thiamine thiazolone diphosphate |
is a significantly better binder to transketolase than thiamine |
|
| 2.2.1.1 | Urea |
denaturation of holo-transketolase by urea displays at least three transitions, where only the final equilibrium denaturation transition is the same for both apo-transketolase and holo-transketolase. Enzyme is deactivated initially by changes in structure associated with the cofactors, but this event does not release the cofactor from the enzyme. Holo-transketolase does not denature to apo-transketolase at 2 M urea. Complete dissociation of cofactors from holo-transketolase at 3.8 M urea without formation of the compact form of apo-transketolase (intermediate form). Holo-transketolase and apo-transketolase at 7.2 M urea both show a common denatured form |
|
| 2.2.1.1 | ZINC12007063 |
i.e. 2-[(2,2-dimethyl-3H-benzofuran-7-yl)oxy]-N-[2-(4-ethyl]-6-oxo-1H-pyrimidin-2-yl)-5-(2-furyl)pyrazol-3 |
|
